First Successful Pivotal Gene Therapy for a Blinding Eye Disease Restores Night Vision

For the first time, a late-stage trial of a gene therapy for X-linked retinitis pigmentosa has hit its main goal.

Beacon Therapeutics reported that laru-zova (laruparetigene zovaparvovec) helped a higher share of treated patients read at least 15 more letters on a low-light visual acuity test after one year than untreated participants. None of the untreated group reached that bar.

XLRP is a severe inherited retinal disease that mainly affects boys and young men. Night vision goes first, and many patients progress toward legal blindness. It accounts for about 14% of retinitis pigmentosa. Until now, there has been no approved disease-modifying treatment.

The VISTA trial enrolled 85 males aged 12 to 48. Twenty-four percent of the low-dose group and 31% of the high-dose group gained 15 or more letters in dim light. Adverse events were predominantly mild to moderate; two serious events were attributed to the surgical delivery, not the vector. Beacon plans to start a rolling regulatory filing by the end of 2026.

Earlier programmes in this disease have disappointed. A Biogen-acquired therapy failed in 2021. MeiraGTx missed its primary objective in a pivotal study. A successful pivotal readout here is doing real work.

Key Facts

• 31% of high-dose patients gained 15+ letters of low-light visual acuity versus 0% of controls
• 24% of low-dose patients reached the same threshold
• 85 male participants, ages 12–48, one year of follow-up
• Rolling approval application planned by end of 2026

Why This Matters

A one-time gene therapy that restores usable night vision would be a first for XLRP. The endpoint was chosen because night blindness is one of the most disabling early features of the disease — a 15-letter gain in low light is a change patients notice.

What We Don't Know Yet

One-year data is not durability. Most treated patients did not hit the 15-letter bar. Two serious surgical events underline that this is an invasive procedure. Secondary endpoints were mixed. Regulatory review is not approval.

Sources: BioPharma Dive · Beacon Therapeutics
Published 21 September 2026 · Category: Health & Medicine